All In Biotech

Drug Trial Radar · NCT04502030

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 247 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

247

Actual

Start

Oct 5, 2020

Primary completion

Sep 19, 2025

Study completion Sep 19, 2025

Sponsor

Lead sponsor
OctapharmaIndustry
Sponsor type
Industry
First posted
Aug 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia

Conditions

  • Chronic Lymphocytic Leukemia
  • Hypogammaglobulinemia

Interventions

  • PanzygaBiological

    Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Major InfectionsTime frame: From first treatment to the occurrence of a major infection or to the end of study visit. The median study duration of participants completing the study was 366 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.

Locations

84 sites in 12 countries. Site status is shown where the registry gives one.

  • Octapharma Research Site

    St. Petersburg, Florida

  • Octapharma Research Site

    Columbus, Georgia

  • Octapharma Research Site

    Macon, Georgia

  • Octapharma Research Site

    New Orleans, Louisiana

  • Octapharma Research Site

    Baltimore, Maryland

  • Octapharma Research Site

    Baltimore, Maryland

  • Octapharma Research Site

    Detroit, Michigan

  • Octapharma Research Site

    Rochester, Minnesota

  • Octapharma Research Site

    Buffalo, New York

  • Octapharma Research Site

    New York, New York

  • Octapharma Research Site

    New York, New York

  • Octapharma Research Site

    Shirley, New York

  • Octapharma Research Site

    Durham, North Carolina

  • Octapharma Research Site

    Charleston, South Carolina

  • Octapharma Research Site

    Houston, Texas

  • Octapharma Research Site

    Brno, Czechia

  • Octapharma Research Site

    Hradec Králové, Czechia

  • Octapharma Research Site

    Ostrava, Czechia

  • Octapharma Research Site

    Aalborg, Denmark

  • Octapharma Research Site

    Herning, Denmark

  • Octapharma Research Site

    Roskilde, Denmark

  • Octapharma Research Site

    Dortmund, Germany

  • Octapharma Research Site

    Frankfurt, Germany

  • Octapharma Research Site

    Kiel, Germany

  • Octapharma Research Site

    Marburg, Germany

  • Octapharma Research Site

    Athens, Greece

  • Octapharma Research Site

    Athens, Greece

  • Octapharma Research Site

    Athens, Greece

  • Octapharma Research Site

    Ioannina, Greece

  • Octapharma Research Site

    Pátrai, Greece

  • Octapharma Research Site

    Thessaloniki, Greece

  • Octapharma Research Site

    Budapest, Hungary

  • Octapharma Research Site

    Debrecen, Hungary

  • Octapharma Research Site

    Győr, Hungary

  • Octapharma Research Site

    Kaposvár, Hungary

  • Octapharma Research Site

    Nyíregyháza, Hungary

  • Octapharma Research Site

    Haifa, Israel

  • Octapharma Research Site

    Haifa, Israel

  • Octapharma Research Site

    Petah Tikva, Israel

  • Octapharma Research Site

    Castelfranco Veneto, Italy

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.